Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.86 UNCHANGED

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

20 21 Next >

Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States

September 19, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

September 16, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder ↗

July 21, 2022

Via Benzinga

Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗

September 16, 2022

Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.

Via Investor's Business Daily

Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries

September 13, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

7 Stocks Under $15 to Buy and Hold Forever ↗

September 01, 2022

For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul.

Via InvestorPlace

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 30, 2022

Via Benzinga

Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate ↗

August 30, 2022

The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of...

Via Benzinga

With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report ↗

August 30, 2022

Via Benzinga

Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26 ↗

August 26, 2022

CNBC The Aviation Sector Is Slammed By Sky-High Rents

Via Benzinga

After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact ↗

August 26, 2022

Via Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 22, 2022

Via Benzinga

Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried ↗

August 22, 2022

Shares hit their lowest point since November on the FDA's decision in HAE.

Via Investor's Business Daily

Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure

August 22, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Peering Into Takeda Pharmaceutical's Recent Short Interest ↗

August 08, 2022

Takeda Pharmaceutical's (NYSE:TAK) short percent of float has risen 18.18% since its last report. The company recently reported that it has 4.18 million shares sold...

Via Benzinga

Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance

July 28, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets ↗

July 27, 2022

BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome...

Via Benzinga

Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease

July 26, 2022

Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could...

Via FinancialNewsMedia

Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents ↗

July 26, 2022

Via Benzinga

Peering Into Takeda Pharmaceutical's Recent Short Interest ↗

July 21, 2022

Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 15.38% since its last report. The company recently reported that it has 3.29 million shares sold short, which...

Via Benzinga

Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

July 21, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022 ↗

July 19, 2022

Upgrades

Via Benzinga

Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful ↗

July 18, 2022

Via Benzinga

Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange

July 11, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Looking Into Takeda Pharmaceutical's Recent Short Interest ↗

July 05, 2022

Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 4.06 million shares sold short, which...

Via Benzinga

Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years ↗

July 01, 2022

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.

Via Benzinga

Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years

June 30, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

June 27, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts

June 22, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

As Health Problems Mount Patients Welcome New Treatments

June 14, 2022

Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...

Via FinancialNewsMedia

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.